The role of the renal kallikrein–kinin system in diabetic nephropathy
Authors:
- 1 January 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 16 (1) , 22-26
Abstract
Purpose of review Diabetic nephropathy is one of the most common complications in diabetes mellitus. Multiple pathogenic mechanisms are now believed to contribute to this disease, including inflammatory cytokines, autacoids and oxidative stress. Numerous studies have shown that the kallikrein–kinin system may be involved in these mechanisms. This review focuses on recent research advance on the potential role of the kallikrein–kinin system in the development of diabetic nephropathy, and its clinical relevance. Recent findings A collection of recent studies has shown that angiotensin-converting enzyme inhibitors, which inhibit angiotensin II formation and degradation of bradykinin, and vasopeptidase inhibitors attenuated the development of diabetic nephropathy in experimental animals and clinical settings. The role of the kallikrein–kinin system in diabetes is further supported by findings that diabetic nephropathy is worsened in diabetic mice lacking bradykinin B2 receptors. Although long-acting bradykinin B2 receptor agonists have been shown to have renal protective effects, their therapeutic benefits have not been well studied. Summary Current experimental investigations demonstrated that pharmacological intervention of the kallikrein–kinin system improved renal conditions in diabetes mellitus. These findings suggest that the kallikrein–kinin system may be a therapeutic target in preventing and treating diabetic nephropathy.Keywords
This publication has 48 references indexed in Scilit:
- Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptorsJournal of Clinical Investigation, 2006
- Cardioprotective mechanisms of the kallikrein–kinin system in diabetic cardiopathyCurrent Opinion in Nephrology and Hypertension, 2006
- Bradykinin B2 receptors – a target in diabetic nephropathyExpert Opinion on Therapeutic Targets, 2005
- Mechanisms through which bradykinin promotes glomerular injury in diabetesAmerican Journal of Physiology-Renal Physiology, 2005
- Inhibition of IGF-I–induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykininKidney International, 2002
- The Development of the Bradykinin Agonist Labradimil as a Means to Increase the Permeability of the Blood-Brain BarrierClinical Pharmacokinetics, 2001
- Two‐chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5The FASEB Journal, 2000
- Endothelial dysfunction in diabetesBritish Journal of Pharmacology, 2000
- Lys-bradykinin stimulates Na+ influx and DNA synthesis in cultured human fibroblastsCell, 1983
- Urinary enzymes, nephrotoxicity and renal diseaseToxicology, 1982